Resetting the clock on age-related somatic mutations
The codon suppressor platform
We restore full-length protein at translation, reading through the premature stop, rather than rewriting every damaged DNA site. Each program is chosen for the biology it rescues, not the footprint it claims.
Artan Codon Therapy addresses a rich landscape with a single molecule
Syenex
Syenex
Syenex
Syenex
Syenex
Syenex
Syenex
Syenex
Leadership
Operators converting platform science into clinical ambition.
Brian Bodemann, Ph.D.
Chief Executive Officer
Ph.D. in pharmacology, UT Southwestern. Leading translation from discovery toward the clinic.
Anthony Schwartz, Ph.D.
Co-Founder & Chief Operating Officer
Two decades building biotech companies across oncology, rare disease, and longevity.
Michael Torres, Ph.D.
Co-Founder & Chief Scientific Officer
Co-founded ReCode Therapeutics and CrossBridge Bio, acquired by Eli Lilly in under three years.
Partners
Science first. Community-backed. Company-executed.
- VitaDAO
- BIO
- Molecule
- Syenex
- spARK Labs by ARK Invest
From concept toward clinical medicine.
We build toward real-world outcomes, moving this science from concept toward clinical medicine.
Get in touch